This was not some random experiment on the population. While the gold standard of a phase three trial was not available to support the longer interval, there was plenty of data about the performance of prior vaccines, and interim data about immunogenicity with a longer interval for the COVID-19 vaccines.
The effects of a single dose were reasonably well understood as well as the impacts on transmission. Reducing transmission is a potentially more relevant goal than individual health outcomes in the grand scheme of things.
Our government decided against the emergency usage in the end, and it was the right decision in hindsight, as it turns out that the vaccine is far less effective than its competitors, and could very well have had similar problems as AZ or Biontech.
There were enough volunteers for them.